

Index

- Abnormalities
 - chromosomal
 - fiber FISH for analyzing, 119–120
 - nomenclature for describing, 91–92
 - structural, causes of, 207–221
- Abortion, spontaneous, 182–183
 - of 45, X zygotes, 285
 - in Down syndrome, 177
 - in Edwards syndrome, 178
 - nondisjunction in, 161–163
 - in Patau syndrome, 178–179
 - in progeny of unbalanced reciprocal translation, 251
 - in translocation carriers, 245–246
 - in translocation trisomies, 243
 - trisomies associated with, 5
- Acentric chromosome, defined, 46
- Acetylation, of transcriptionally active chromatin, 72
- Acetyltransferase, 73
- Acrocentric chromosome
 - defined, 46
 - ribosomal RNA genes of, 55–56
- Actinomycin D, binding to GC base pairs, 85
- Acute lymphatic leukemia (ALL)
 - apoptosis inhibition in, 407–408
 - t(9;22) translocation in, and oncogene activation, 411
- Acute myelogenous leukemia (AML)
 - t(15;17) associated with, 407
 - t(9;12) translocation in, and oncogene activation, 411

Index

- Adenomatous polyps of the colon gene (*APC* gene), tumor suppression by, 425–426
- Adenylate adenosine monophosphate deaminase 2 gene (*AMPD2* gene), intrachromosomal amplification of, 376–377
- Age/aging
 - of cells, 40–41
 - maternal
 - and nondisjunction, 164–165
 - and spontaneous abortion frequency, 182
- Alleles, differing, linkage analysis dependence on, 432
- Alu*-polymerase chain reaction (*alu*-PCR), 118
- Alu* repetitive sequences
 - characteristics of, 99
 - R-banding from in situ hybridization of, 89
- Amniotic fluid, cells from, determination of fetal chromosomal constitution from, 4
- Amplification
 - of a cholinesterase gene, after exposure to organophosphates, 373
 - and oncogene activation, 411
 - See also* Gene amplification
- Amplisomes, defined, 372
- Anaphase
 - II, male and female differences in, 134–135
 - transition to, and regulation of, 23–24
- Anaphase-promoting complex (APC), 18
- Androgen insensitivity syndrome, testicular tumor development associated with, 262
- Aneuploidy
 - autosomal, phenotypes due to, 175–185
 - defined, 157
 - in sibs, for different chromosomes, 165
 - of somatic origin, 170–171
- Angelman syndrome (AS), 314–315
 - critical regions for, 325–327
 - deletion in, 213, 224
 - FISH demonstration of, 110, 193
 - involvement of the *MN7* gene, 215
- Antibody banding, 87–88
- Anticipation
 - in fragile X syndrome, 301
 - in trinucleotide expansion, 303
- Aphidicolin, induction of fragile sites by, 295
- Apoptosis
 - blocking of, in cancer cells, 379
 - delay of, by oncogenes, 407
 - after double-strand breaks, 151
 - of female germ line cells, 135–136
 - mediation by DAP kinase, 426
 - of oocytes, in Turner syndrome, 285
 - reduction of, in xeroderma pigmentosum, 362
- Arm ratio, chromosomal, defined, 46
- Ataxia telangiectasia (AT), 353
 - cell cycle checkpoint disorder in, 359–360
 - sensitivity to ionizing radiation and radiomimetic drugs in, 208–209
 - terminal attachments of chromosomes in, 212
- Ataxia-telangiectasia mutated (ATM) protein, activation of, in DNA damage, 19
- AT base pair queues, correspondence with the chromosome scaffold, 67
- ATPases
 - cytoplasmic dynein, 53
 - SCII, of the chromosome scaffold, 65
- Autoradiography, for in situ hybridization analysis, 108–109
- Autosomes, evolution of, 451–452
- Azoospermia
 - in deletion from the Y chromosome, 455
 - in deletion from the Y long arm, 263
 - in t(X;A) males, 291
- Bacterial artificial chromosomes (BACs), cloning with, 8–9, 115–116, 440
- Bacteriophages, cloning with, 8
- Banding, 6–7, 79–94
 - functional significance of, 103
 - identification of chromosomes by, 47

- molecular correlates of, 95–105
See also G-banding, Karyotype, Q-banding, R-banding
- Barr body, 267
 defined, 6
See also X chromosome, inactive
- Base pairs, number of, in the human genome, 62
- Beckwith-Wiedemann syndrome (BWS), 313–314
 cancers associated with, 422
- Benzpyrene, binding of, to p53, 396
- Bivalent chromosomes, 136
 at pachytene, 129
 at prometaphase, 134
 XY, synaptonemal complex of, 158
- Bloom syndrome (BS), 353–356
 cell fusion in, 340, 344
 isodisomy 15 resulting in, 311
 mitotic crossing over in, 332
 symmetric dicentrics in, 194
 triradials in, 333
- B lymphocytes, differentiation of, inactive genes during, 72
- Bone marrow cells, endoreduplication of, 332
- Bouquet formation, zygotene stage of meiosis, 127–129
- Breakpoints, in paracentric inversions, 196–197. *See also* Hotspots
- Breast cancers, familial, loss of heterozygosity in, 417
- Bromodeoxyuridine (BrdU)
 fragile site induction by, 295
 replication banding patterns visualized with, 31, 35, 85
 for replication timing by fluorescence in situ hybridization, 114
- Burkitt lymphoma
 chromosomal translocation in, 407
 steps in development of malignancy, 389
- Cadherins, mapping of genes for, and loss of heterozygosity, 425–426
- Caenorhabditis elegans*, genome of, 448
- Caffeine, inhibition of a DNA damage checkpoint, 52
- Campomelic dwarfs, XY, mutation in the SOX9 gene in, 261
- Camptothecin, induction of fragile sites by, 295
- Cancer/carcinoma
 association with chromosome instability syndromes, 353, 394
 common fragile sites associated with, 295–297
 E-cadherin absence in epithelial cancers, 425–426
 gene amplification in, 376
 genome destabilization in, 10, 385–403
 hypomethylation of DNA in, 451
 inactivation of tumor suppressor genes in, 415–430
 loss of heterozygosity in, 297
 region 20q13.2–q13.3 amplification in, 147
 telomerase of cells in, 40–41
See also Oncogenes; Protooncogenes; Translocation
- Carcinogenesis
 role of cell cycle regulatory genes in, 14–16
 role of gene amplification and overexpression in, 379
 two-hit model of, 417–418
- CATCH22 syndrome, deletion in, 213, 231–232. *See also* Di George syndrome
- β -Catenin, binding to APC protein, 425–426
- C-banding, 81–83
 differential, between two chromatids, 85
See also Constitutive heterochromatin
- cDNA library, reverse transcriptase for preparing, 442, 470
- Cell adhesion, genes affecting, 425–426
- Cell cycle
 G₀ resting state following differentiation, 14
 G₁ (Gap₁) phase, 14
 arrest at, by cyclin dependent kinase inhibitors, 19
 DNA checkpoint functioning in, 395–396, 419
 chromosome breaks in, 188–190

- Cell cycle (*cont.*):
 - G2 (Cap2) phase
 - of interphase, 14
 - chromatid breaks in, 190–191
 - genes affecting, 420–421
 - interphase of, 14
 - mitotic, 13–27
 - regulators of, tumor suppressing, 419
 - See also* Leptotene; Meiosis; Metaphase; Mitosis; Prometaphase; Prophase; Synthetic phase; Telophase; Zygotene
- Cell differentiation
 - blocking of, by oncogenes, 406–407
 - chromosome changes in, 323–338
- Cell division cycle (CDC) proteins
 - CDC6
 - binding to an origin of replication complex, 39
 - phosphorylation by cyclin E/CDK2, 33
 - in transition from metaphase to anaphase, 23
- Cell fusion
 - spontaneous, 340
 - in Bloom syndrome, 354
 - for studying DNA replication, 39
 - for studying Fanconi anemia, 358–359
- CentiMorgan, defined, 432
- Central element, of the synaptonemal complex, 143
- Centric fission, 195
- Centric fusion
 - isochromosomes resulting from, 195
 - Robertsonian translocation from, 200
- Centriole, 22
- Centromere, 49–54
 - cohesion in meiosis I, 134
 - embryonic inactivation of excess, 329–331
 - evolution of, 456–457
 - location of, 45–46
 - misdivision of, 195–196
 - in Robertsonian translocations, 199–200
- Centromere index, defined, 46
- Centromeric proteins (CENPs), functions of, 52–53
- Centrosome
 - aberrant, spindle aberrations associated with, 392
 - in interphase and mitosis, 22
- Centrosome-associated kinase, in cancers, 392
- Chaperones, molecular, Hsp70 proteins as, 145
- Charcot-Marie-Tooth disorder
 - critical region for, 232
 - double-strand breaks in, 215
- Checkpoints
 - cell cycle, 19–20
 - disordered in ataxia telangiectasia, 359–360
 - requirement for p53 protein by, 374–379
 - DNA damage
 - meiotic, 149–151
 - and structural instability of chromosomes, 395–396
 - spindle assembly, 23
- Chemistry
 - of chromosomes, 61–77
 - of DNA replication, 31–33
- Chiasma, 129
 - frequency of, per cell, 132–133
 - meiotic, 129, 133
 - defined, 126
 - effect on bivalents, 165–166
 - mitotic, between homologous chromosomes, 356–357
- Chiasma interference, 132–133
- Chimera, 315–317
- Chip technology, for gene studies, 471
- Cholinesterase gene, amplification of, in a family exposed to organophosphates, 373
- Choriocarcinoma, arising from hydatidiform moles, 318
- Chromatin
 - conformation of
 - and protein content of bands, 102–103
 - restoration after replication, 41–42
 - defined, 61
 - loops of, chromosomal, 63–67

- mitotic, cyclin B/CDK1 role in, 18
 - organization of, 150
 - SNF₅*, role in remodeling of, 423
 - Chromatin assembly factor 1 (CAF-1), nucleosome assembly by, 41–42
 - Chromomycin, binding to GC base pairs, 85
 - Chromosomal instability phenotype (CIN phenotype), in colorectal cancer, 392–394
 - Chromosome breaks, 188–191
 - induced, in radiation hybrids, 347
 - See also* Deletions; Double-strand break; Hotspots; Insertion; Inversion; Recombination; Ring chromosome; Translocations
 - Chromosome complement, composition of, 47
 - Chromosome condensation
 - premature, 341–343
 - in prophase, 20
 - Chromosome core, defined, 63
 - Chromosome instability syndromes, 353–367
 - genetic basis of, 359
 - Chromosome mapping. *See* Mapping
 - Chromosome number, human, 3–4
 - Chromosome Orientation and Direction FISH (COD-FISH), 111
 - Chromosomes
 - abnormalities of, frequencies, 162
 - abnormal numbers of, 157–174
 - breakage of, studying with premature chromosome condensation, 341–342
 - changes in cell differentiation, 323–338
 - in confined placental mosaicism, 310–311
 - evolution of, 447–461
 - homologous, pairing of, 142
 - human
 - early study of, 2–11
 - mapping of, 431–446
 - in maternally derived and paternally derived uniparental disomy, 310
 - preferential loss from rodent-human hybrids, 345–347
 - structural changes in, 394–395
 - See also* Translocations
- 1
- in ICF syndrome and other multiradials, 333–335
 - isodisomy in pycnodysostosis, 311
 - mapping of *KISS1* tumor suppressor gene to, 426
 - mapping of the Duffy blood group locus to, 435–436
 - mapping of the synaptonemal complex protein 1 gene to, 143
- 2
- intrachromosomal insertion in, paternal, 249
 - mapping of *BUB1* protein kinase gene to, 434
 - origin in fusion, 451
- 3
- Fanconi D mapped to, 359
 - fragile site FRA3B of, 295–297
 - telomerase RNA gene on, 386
 - von-Hippel-Landau gene *VHL* on, 425–426
- 4
- deletion from, in Wolf-Hirschhorn syndrome, 6
 - mapping of the Huntington disease gene to, 304
 - translocation (X,4)(q22;q24), 277
- 5
- deletion from in cri du chat (cat cry) syndrome, 5–6, 192, 224–227
 - DNA damage checkpoint gene mapped to, 397
 - ideograms, with and without translocation, 120
 - isodisomy in spinal muscular atrophy, 311
 - mismatch repair gene *MSH3* on, 450
 - RAD50* deletion in acute myeloid leukemia, 397
 - tumor suppressor gene loss on, in colon, carcinoma, 423
- 6
- database for, Web address, 100
 - deletions in, and cancer, 386

Index

- Chromosomes (*cont.*):
- Fanconi E mapped to, 359
 - major histocompatibility complex gene locus on, 98
 - major histocompatibility complex gene *MHC* contig map, 441
 - major histocompatibility complex gene *MHC* mapping to, 436
 - suppression of malignant melanoma metastasis with, 426
- 7
- CDK6* mapped to, 412
 - in cystic fibrosis, 311
 - deletion from in Williams-Beuren syndrome, 213
 - deletion from in Williams syndrome, 229–230
 - duplications in Williams-Beuren syndrome, 224
 - insertion of rRNA gene cluster into the long arm of, 299
 - inversions in, 451
 - paracentric inversion on, 451
 - Robertsonian translocation *t(7;7)(p10;q10)* in, 243–244
- 8
- deletion from in Duane syndrome, 228
 - deletion from in Langer-Giedion syndrome, 230
 - gene for Nijmegen breakage syndrome on, 361
 - mosaicism of, 181
 - translocation with 14 in Burkitt lymphoma, 407
- 9
- Fanconi C mapped to, 359
 - Fanconi G mapped to, 359
 - genes for p16 and p19 on, 420–422
 - in ICF syndrome, 333–335
 - interferon gene family on, 449
 - isodicentric, 194
 - mapping of the *DMRT1* gene to, 329
 - monosomy of, and sex reversal, 261–262
 - ring phenotype, 227–228
- 10
- deletion from in carcinomas, 423–424
 - fragile site induction by BrdU, 295
 - MXI1* mapped to, cancers associated with, 423
- 11
- autosomal imprinting clusters on, 313, 326
 - in Beckwith-Wiedemann syndrome, 422
 - in Beckwith-Wiedemann syndrome, paternal imprinting in, 313–314
 - cyclin D1 gene on, 411
 - KIP2* tumor suppressor on, 422–423
 - loss of imprinting on, in Wilms tumors, 398
 - mapping of *MEN1* to, 424
 - mapping of *ATM* to, 360
 - MRS11* gene alteration in cancer, 397
 - tumor suppression by, genes responsible for, 415–416
- 13
- physical mapping of the retinoblastoma gene on, 437
 - syndromes from deletion in, 223–224
 - trisomy of, 5, 178–179
 - trisomy of, holoprosencephaly associated with, 224
 - trisomy of, mosaic, 181
- 14
- breakpoints in a pericentric inversion, 248
 - immunoglobulin heavy chain gene on, 407
 - in translocation *t(X;14)* with spreading of inactivation, 277
- 15
- association with the sex vesicle, 137
 - autosomal imprinting clusters on, 313
 - in Bloom syndrome, 354
 - deletion from in Prader-Willi syndrome, 213–214, 224
 - deletion from in Williams-Beuren syndrome, 213–214
 - duplication in, partial trisomy, 193–195
 - inverted duplication in, 217
 - in Angelman syndrome, 314–315
 - paternal, in Prader-Willi syndrome, 314
 - uniparental disomy of, and skewed X inactivation, 271–272
 - uniparental disomy of, in Bloom syndrome, 311

- 16
 deletion from in Rubinstein-Taybi syndrome, 228
 Fanconi A gene mapped to, 359
 fragile site induction on, effect of BrdU, 295, 299–300
 frequency of nondisjunction of, 163
 in ICF syndrome, 333–335
 mapping of the α -haptoglobin locus to, 436
 trisomy of, expectations in, 311
 trisomy of, maternal origin of, 169
- 17
 deletion from in Miller-Dieker syndrome, 231
 deletion from in Smith-Magenis syndrome, 230
 duplication in, resulting in Charcot-Marie-Tooth disease, 232
 mapping of the thymidine kinase gene to, 436
 SOX9 gene on, sex-determining role of, 261
- 18
 deletion from, phenotypes in, 6
 trisomy of, 5, 178
 trisomy of, and meiotic oocyte characteristics, 138
 trisomy of, maternal origin, 169
 trisomy of, mosaic, 181
- 19
 association with molar pregnancies, 319
 locus of origin of replication of the gene for lamin B2, 34
 mapping of the poliovirus receptor gene to, 436
- 20
 gene for ICF syndrome on, 333–335
 gene for SPO11 on, 147
- 21
 in humans and Pongidae, 452
 maps for, 439
 in translocation t(X;21), 277
 trisomy in Down syndrome, 4–5, 176–178
 trisomy in Down syndrome, reproductive consequences, 138
- 22
 deletion from in Di George syndrome, 213, 224, 231–232
 deletion from in malignant rhabdoid childhood cancers, 423
 hotspot for rearrangement on, 451
 length of ribosomal RNA genes on, 119–120
 Robertsonian translocation in, 243
 trisomy of, 180
 Chromosome-specific library, 117
 Chronic myelogenous leukemia (CML)
 chromosomal changes during progression of, 389
 t(9;22) translocation in, 409
 t(9;22) translocation in, and oncogene activation, 411
 Cigarette smoking, breaks at fragile sites associated with, 376
 Circular deoxyribonucleic acid, 370
 Clastogens
 assay for, 31
 defined, 207
 Cloning
 in bacterial artificial chromosomes, 440
 of DNA fragments, 8, 114–117
 in yeast artificial chromosomes (YACs), 346, 440
 C-mitosis, in cancer cells, 392
 c-MOS gene, cytostatic factor produced by, 135–136
 c-MYC, origin of replication of, 34
 Codons
 defined, 3
 stop, defined, 442
 Cohesion phosphoprotein pREC8, 134
 Coiled bodies (CBs), transcription by RNA polymerase II in, 69–70
 Colchicine, effect on cell division, 4
 Colon cancer/carcinoma
 amplification of the MYC gene in, 411
 changes in cells, and malignancy of, 389
 Colorectal cancer, phenotypes in, 392
 Comparative genomic hybridization (CGH), 121
 Confined placental mosaicism (CPM), 181, 310–311

Index

- Confined placental mosaicism (CPM) (*cont.*):
evaluating the potential danger of,
312–313
- Confocal laser-scanning microscopy, for
examining sites of replication, 37
leptotene, 127
- Conservation, of chromosomes, 451
- Constitutive heterochromatin (C-band), 82
repetitive sequences in, 101
timing of replication and location of,
67–68
visualization of, 56
- Contig, defined, 440
- Contig map, major histocompatibility
complex gene of chromosome 6, 441
- Contiguous gene syndromes
defined, 223
X-linked, 289–290
- Cosmids, cloning with, 8, 115
- Cot value, for assessing renaturation of
DNA, 107–108
- Counterstaining, to enhance banding
patterns, 86–87
- CpG clusters, unmethylated, 98, 374–379
- Cri du chat (cat cry) syndrome, deletion
from chromosome 5 as the cause of,
5–6, 192, 224–227
- Critical regions
for Angelman and Prader-Willi
syndromes, 325–327
for Beckwith-Wiedemann syndrome,
313–314
for deletion syndromes, 228–231
for Down syndrome, 232–233, 439, 464
for Turner syndrome, 285–287
WHSC1 gene for, fusion of *IgH* with, in
multiple myeloma, 410
for X inactivation, 272–274
- Crossing over
frequency of, 133
in meiosis, 126, 129
Y chromosome, 257
in mitosis, 356–357
in Bloom syndrome, 332
suppression by topomerase II, 65
protein MLH1 at the sites of, 148
recombination nodule role in, 145
unequal, results of, 449–450
between X and Y chromosomes,
consequences of suppression of,
453–455
- Cyclin-dependent kinases (CDKs)
activation of, 33
in the cell cycle, 14
by cyclins, 16
CDK1, phosphorylation of Eg5 by, 22
CDK6, amplification of the gene for, 412
inhibitors of
effect on the cell cycle, 420–421
p57, 422–423
mediation of mitosis by, 18
- Cyclins
activation of cyclin-dependent kinases by,
16
A1, expression of the gene for in meiosis,
328–329
B/CDK1
mitosis-promoting factor, 134–136
in mitotic chromatin, 18
D1, amplification of the gene for in
cancers, 411
D2, amplification of the gene for in
ovarian and testicular cancers, 412
E
activation leading to initiation of the S
phase of the cell cycle, 18, 425–426
E/CDK2
anchorage dependent activation of,
425–426
for centrosome duplication in the S
phase of the cell cycle, 22
synthesis of, triggering of, 14
- Cytogenetics
clinical, development of, 4–6
human, 1–11
future of, 463–473
- Cytokinesis
defined, 14
protein PRC1 role in, 24
- Cytrophotometry, for determining DNA
content of chromosomes, 48
- Cytostatic factor (CSF), arrest of oocyte
division by, 135–136
- Daughter nuclei, centromere role in
transport of proteins into, 54

- Deletions
 chromosomal, 190–193
 chromosomal D group, in retinoblastoma, 5
 chromosomal G group, in chronic myelogenous leukemia, 5
 in the Prader-Willi syndrome, 326–327
 syndromes due to, 223–237
 X chromosome, effect on males, 289–290
- Denaturation, of DNA, 107
- Deoxyribonucleic acid (DNA)
 composition of, in the genome, 62
 control of replication of, 38–40
 determining the content of, in chromosomes, 48–49
 historical demonstration of gene composition as, 2
 left-handed, 87–88
 loops of, availability to transcription factors, 71
 methylation of, and cancer, 397
 programmed loss of, in cell differentiation, 324
 replication of, 29–44
 error-prone, in xeroderma pigmentosum, 362
 satellite, types of, 101
 sequence variation in the genome, 432–433
 sequencing of nucleotide bases in, 8
See also Checkpoints
- 4',6-Diamidino-2-phenylindole (DAPI), binding to AT base pairs, 85–87
- Dicentric chromosomes
 formation of, leading to gene amplification, 375
 inactivation of one centromere of, 329–330
- Dictyotene stage, arrest of oocyte division at, 134–136
- Diepoxybutane (DEB), sensitivity of Fanconi anemia cells to, 358–359
- Di George syndrome, deletion in, 213, 224, 231–232
- Diplochromosomes, 31
- Diploid gametes, origin of, 169–170
- Diplotene stage, 129–130
 chromosomal univalents at, 157
- Disomy, incidence in sperm, 161. *See also* Uniparental disomy
- Distamycin A
 binding to AT base pairs, 85
 fragile site induction by, 295–296
 sensitivity to, 300
- DNA. *See* Deoxyribonucleic acid
- DNA ligase
 of DNA factories, 33
 in replication of chromosomal DNA, 31–33
- DNA methylase, of DNA factories, 33
- DNA methylation, 40
 blocking LINE and SINE transcription by, 450–451
- DNA polymerases, α and σ , of DNA factories, 33
- Domains
 chromosome, in the interphase nucleus, 67–68
 matrix attachment regions as boundaries of, 70
- Dosage compensation, equalizing expression levels of X-linked genes in males and females, 452–456, 465
- Dosage compensation, equalizing expression levels of X-linked and autosomal genes, 465
- Double aneuploidy, human, discovery of, 5
- Double minutes, 369, 370–372
 in colon carcinoma, *MYC* gene amplification reflected in, 411
 origin of, 373
- Double-strand break (DSB), 207–208
 genes involved in repair of, 397–398
 initiation of ectopic homologous exchange in, 215
 in lymphocyte differentiation, 324
 repair model, 147, 209
- Down syndrome, 176–178
 absence of, t(X;21) translocation, 277
 critical region for, 232–233, 439, 464
 historical determination of trisomy 21 in, 4
 maternal r(21) in, 228
 risk of, in Dq21q carriers, male and female, 245

Index

- Down syndrome (*cont.*):
 Robertsonian translocation as a cause of, 5
 in rob(21;21)(q10;q10) translocation families, 243–245
 tertiary trisomic progeny in, 138
 trisomy/disomy mosaicism in, 180–181
- Duane syndrome, critical region for deletion in, 228
- Duffy blood group locus, assignment to chromosome 1, 435–436
- Duplication, proteolipid protein gene; in Pelizqueus-Merzbacher syndrome, 119–120
 transpositional, adrenoleukodystrophy (ALD), 457
- Duplications
 partial trisomies, 193–195
 syndromes due to, 223–237
 X chromosome, effects on males, 289–291
 See also Mosaicism; Trisomy
- Dynein
 complex with nuclear mitotic apparatus protein, 22
 of kinetochores, 53
- Dystrophin gene, origins of replication in, 34
- Ectopic recombination, 449
 of Y-linked genes, 455
- Edwards syndrome, 178
- Elastin, gene for, 229
- Electron microscopy, for kinetochore visualization, 51
- Embryogenesis, *HOX* gene role in, 467
- Emerin, defective, in Emery-Dreifuss muscular dystrophy, 450
- Emery-Dreifuss muscular dystrophy, 450
- Endomitosis
 defined, 332
 in malignant cells, 389
- Endoreduplication, 331–333
 in malignant cells, 389
- Environment, causes of cancer in the, 398–399
- Epigenetic processes
 defined, 41–42
- Episomes, defined, 372
- Epstein-Barr virus, infection by, and cancer development, 418
- Equatorial meiotic division, defined, 125
- Erythropoiesis, programmed DNA loss in, 324
- Euchromatin, transcription from, 71
- Eukaryotes
 defined, 13
 origin of, 448
- Euploidy, 309–322
- Evolution
 of chromosomes, 447–461
 conservation of histone structure in, 62–63
 of gene amplification, 449
- Ewing sarcoma, t(11;22) translocation in, and oncogene activation, 411
- Exogenous causes of structural aberrations, 210–212
- Exons
 defined, 8
 of protein-coding genes, 442
 shuffling of, evolutionary results, 449
- Expressed sequence tag (EST), as a molecular marker, 442
- Facultative heterochromatin, 56
 timing of replication and location of, 67–68
- Facultative heterochromatinization, of an autosome segment, 291
- Familial breast and ovarian cancer syndrome
 mutation of *BRCA1* in, 387–388
- Familial multiple endocrine neoplasia type 1, 424
- Fanconi anemia (FA), 353, 357–359
 triradials in, 333
- Females
 meiosis in, 134–136, 160
 spindle assembly checkpoint absence, 151
 recombination frequencies in, 132–133
 XY, with deletion of the testis-determining factor, 260
 See also X chromosome
- Fertility, male, genes involved on the Y chromosome, 259, 455

- Feulgen reaction, 2
- Fiber, deoxyribonucleic acid, chromosome compaction role of, 63
- Fiber autoradiography, 34
- Fiber fluorescence in situ hybridization, for gene sequence determination, 119–120
- Field inversion gel electrophoresis (FIGE), amplified oncogene identification with, 372
- Filter hybridization, for determining time of replication of genes, 38
- Flow cytometry, for determining DNA content of chromosomes, 48
- Flow karyotype, 49–50
- Fluorescence in situ hybridization (FISH), 8, 109–114
for examining chromosomes in meiotic prophase, 127
for examining the interphase nucleus, 68
for identifying origins of replication, 34
for identifying replication time of *XIST* and *FRM* alleles, 37
for mapping cell cycle regulatory proteins, 18
studies using, in Wolf-Hirschhorn syndrome, 227
- Folic acid, fragile site induction by lack of, 295
- Fragile sites, 295–308
FRAXA and *FRAXE*, 299–300
- Fragile X syndrome, premutation, male and female difference in heritability of expansion, 301
- Fusion
of an interphase and a metaphase cell, 342
neoncogene formation by, translocation in, 411
- G1 phase (Gap1 phase). *See* Cell cycle, G1 (Gap1) phase
- G2 phase (Gap2 phase). *See* Cell cycle, G2 (Gap2) phase
- Gametes
aneuploid, parental origin of, 168–169
number of chromosomes of, 47
- G-banding, 83
with antibodies to adenosine, 87
isochores L1 and L2 associated with, 97
in the synthesis phase, 85
- Gene amplification, 369–383
evolutionary role of, 449
- Gene clusters, functional constraints on, 466
- Gene dosage, critical genes responsible for, 464
- Gene expression, regulation of, 70, 347–348
- Genes
autosomal
imprinted, 312
in male sex determination, 261–262
conditional silencing of, 470
duplication of, and genome plasticity, 448–449
encoding cell cycle regulatory proteins, 15
germline-specific expression of, 328–329
identification with chromosomes
historical, 2
synteny groups, 435–437
immediate early response, 14
inactivation of, by hypermethylation, 422
male-determining, localization to Yp, 259–260
mismatch repair, 450
of the PAR1 region of sex chromosomes, 259
for thymidine kinase, mapping to chromosome 17, 436
tumor suppressor, 386
imprinted, 421–423
of the Y chromosome, in the pseudoautosomal region, 258
See also Globin gene
- Genes, specific
ATM
mapping to chromosome 11, 360
role in G1 DNA damage checkpoint function, 395–396
AZF, in male fertility, 455
BLM, in Bloom syndrome, 354
BRCA1
mutation in familial breast and ovarian cancer syndrome, 387–388

Index

- Genes, specific (*cont.*):
- tumor suppressor, 417, 420–421
 - BUB1*, mutation in cancers, 394
 - BUB*, budding uninhibited by benzimidazole, 23
 - CBP*, mutation in Rubinstein-Taybi syndrome, 228–229
 - CIP1* CDK inhibitor, 386
 - CUL2*, role in cell cycle protein degradation, 425–426
 - DAZ* family, of the Yq, 263, 455
 - diaphanous*, effect on fertility, 329
 - DMRT1*, male germline-specific, 329
 - ELN*, for elastin, 229
 - ETS2*, overexpression in Down syndrome, 233
 - factor 8C, 216
 - FMR1*, inactivation of, 303
 - FOS*, 14–15
 - H19*
 - effect on *IGF2*, 326–327
 - tumor suppressor, imprinted, 421
 - ICF*, mapping to chromosome 20, 333–334
 - INK4A* CDK inhibitor, 386
 - JUN*, 14–15
 - KIP2*
 - of maternal chromosome 11, 313–314
 - tumor suppressor, 422–423
 - KISS1*, suppression of metastasis by, 426
 - LIMX1B*, haploinsufficiency of, in nail-patella syndrome, 228
 - MAD*, mitosis arrest deficient, 23
 - MAD2*, expression in breast cancer, 394
 - MDM2*, interaction with p53 protein, 394
 - MECP2*, mutation in Rett syndrome, 74
 - MEN1*, mutations in familial multiple endocrine neoplasia type 1, 424
 - MNB* (minibrain), in Down syndrome, 233
 - MSH6*, cancers associated with mutation of, 397
 - MYC*
 - amplification in colon carcinoma, 411
 - overexpression in colon carcinomas, 423
 - NBS1*, 361
 - OCT-4*, transcription factor in totipotent cells, 141–142
 - PTEN* tumor suppressor, 423–424
 - PGK*, in the male germline, 328–329
 - RAD1*, role in cell cycle DNA damage checkpoint, 397
 - RB1* tumor suppressor, 386
 - mechanism of action, 418
 - role in cell cycle regulation, 16–18
 - RCC1*, *Alu* sequences of, 99
 - SCP1*, mapping of, 143
 - SEN6*, senescence-inducing, 386
 - SHOX*, mapping to the pseudoautosomal region of the sex chromosomes, 285–286
 - SNF5* tumor suppressor, 423
 - SNRPN*, loss of, in Prader-Willi syndrome, 326–327
 - SOD*, in Down syndrome, 233
 - SOX*, family of, 261
 - SOX9*
 - expression of, and isochore relationships, 97
 - locus control region of, 70
 - SRY*
 - role in sexual development of males, 9
 - sex-determining region Y, 260
 - STK15*, association with aneuploidy, 392
 - TP53*
 - involvement of products in apoptosis, 136
 - mutation in, and ectopic homologous recombination, 214
 - role in G1 DNA damage checkpoint, 395–396
 - role in spindle assembly checkpoint, 19, 394
 - role in tumor suppression, 386, 419–420
 - VHL*, loss of, leading to malignancy, 425–426
 - WAF1*, p21 product of, 33
 - WRN*, 361
 - XIST*, 272–274
 - RNA transcript of, inactivation of an X chromosome by, 277–278
 - of the inactive X chromosome, 9
 - ZIC2*, mapping to 13q32, 223–224
- Gene targeting, 349

- Genetic code, historic specification of, in terms of codons, 3
- Genetic linkage maps, 432–434
molecular hybridization for constructing, 9
- Genetic recombination, 126, 132–133
- Genetics
of chromosome instability syndromes, 359
somatic cell, 7
- Genome
content of, 62
destabilization of, 385–403
haploid, estimation of size of, 2–3
organization of, 465–469
plasticity of, 447–461
See also Human Genome Project
- Genomic imprinting
defined, 9
deletion syndromes involving, 230–231
as an example of facultative heterochromatinization, 324
nature and mechanism of, 325–327
- Genotype, *RB/rb* or *Rb/-*, in retinoblastoma, 417–418
- Giemsa staining, for C-banding, 81–83
- β -Globin, origin of replication of the gene for, 34
- Globin gene
 α , 466
 β , hotspot for recombination near, 146
 ϵ , 466
- Globin gene cluster, β
locus control region of the gene for, 39, 70
timing of replication of, 38
- Glycogen storage disease, from deletion in the phosphorylase kinase subunit B gene, 214
- α -Haptoglobin locus, mapping to chromosome 16, 436
- Heat shock proteins, HSPA2, in synaptonemal complex, 145
- Helicase mutation, in Werner syndrome, 354
in Bloom syndrome, 354
- Hemizyosity, risks associated with, 289–290
- Hemophilia
A
inversion in the gene for, 216–217
long interspersed elements associated with, 100
microscopic inversion at Xq28 in, 247
- Hereditary neuropathy with liability to pressure palsies (HNPP), double-strand breaks in, 215
- Hereditary nonpolyposis colon cancer (HNPCC), long patch repair gene mutation in, 397
- Heritable fragile sites, 299–300
- Hermaphrodite, from fusion of different zygotes, 315
- Herpes virus type 16 (HPV16), spontaneous integration site in FRA3B, 297–298
- Heterochromatin
constitutive versus facultative, 56, 71–72
facultative, 324–325
pericentromeric, Polycomb protein complex associated with, 72
timing of replication of, 35
- Heterochromatin protein, binding to centromeric heterochromatin, 51
- Heterokaryons, complementation analysis in, 340–341
- Heteromorphisms
in satellites and acrocentric chromosomes, 82
in Y chromosomes, 256–257
- High mobility group protein 1/Y (HMG1/Y), of the chromosome scaffold, 65
- High-resolution banding, 84–86
nomenclature for describing, 89–91
- High-resolution fluorescence in situ hybridization, 118–120
- Histone acetylase, p48 subunit of chromatin assembly factor-1, 41–42
- Histone deacetylase
HDAC1, tissue-specific gene repression role of, 16–17
methyl-cytosine binding protein 2 associated with, 73
- Histone genes, transcription of, 69–70

Index

- Histones
 - activity in assembly of chromatin, 41–42
 - defined, 62–63
 - locations in bands, 102–103
 - modification of, 72–74
 - phosphorylation of, leading to
 - chromosome condensation, 18, 20
- Holoprosencephaly
 - mutations of the *ZIC2* gene associated with, 224
 - in trisomy 13, 179
- Homogeneously stained regions (HSRs), 369
 - in colon carcinoma, *MYC* gene amplification reflected in, 411
 - replication of, 370–371
- Homologous chromosomes, pairing of, 142
- Homologous recombination, defined, 348–349
- Homozygosity mapping, 434
- Hotspots
 - common fragile sites as, 295–297
 - interspersed repeats as, 215–217
 - for rearrangement, on chromosome 7, 396
 - for recombination, 146, 187, 211–212
 - in Bloom syndrome, 356–357
 - in Charcot-Marie-Tooth disorder, 215
 - on chromosome 7, 451
 - ectopic Xp-Yp, 259–260
- Housekeeping genes, 325
 - CpG clusters of, 98
 - timing of replication of, 38
- Human artificial chromosomes, 472
- Human Genome Project, 10, 440–443, 471
- Human papilloma virus (HPV)
 - cancers associated with, 398–399
 - RB protein inactivation by, in uterine cervical cancers, 418
- Hunter syndrome, inversion mutation in, 215–217
 - iduronate sulfatase (IDS) deficiency in, 216–217
- Huntington disease (HD), trinucleotide expansion in, 304
- Hybrid cells, growth of, in selective culture media, 343–345
- Hybridization, somatic cell, in cytogenetic analysis, 339–351
- Hydatidiform moles, 318–319
 - from tetraploids, 170
- Hydrogen bonds, role in nucleotide base pairing, 3, 107
- Hygromycin phosphotransferase gene, as a selectable marker, 348
- Hypermethylated-in-cancer-1 gene (*HIC1* gene), 421
- ICF syndrome
 - hypomethylation of chromosomes in, 333
- Ideogram
 - chromosome 5, with material from chromosome 11, 120
 - defined, 47
 - Paris conference standard, 89–91
 - in segmental aneusomy syndrome, examples, 229
- Immunofluorescence, for studying ribosomal RNA transcription, 55
- Immunoglobulin gene clusters, and antibody specificity, 467
- Immunoglobulin heavy chain (IgH), gene locus at 14q32.3, 407
- Imprinting
 - changes in, associated with
 - demethylation, 398, 413
 - disorders involving, 313–315
 - effect on gene activation, 311–313
 - erasing, 328
 - genomic
 - defined, 9
 - deletion syndromes involving, 230–231
 - H19* gene, effect on *IGF2*, 326–327
 - maternal, effect in Turner syndrome, 285
 - sex-specific, 328–329
 - tissue-specific, 325
 - and tumor suppressing genes associated with cancers, 421–423
- Inactivation, spreading of, t(X;14) translocation, 277. *See also* X chromosome, inactive
- Incontinentia pigmenti mutation, skewed X inactivation in, 271–272
- Inner centromeric protein (INCENP), 51
- Insertion
 - intrachromosomal

- and interchromosomal, 200–201
- unbalanced karyotypes from, 249
- inverted
 - progeny resulting from, 249–250
 - recombinant chromosomes from, 250
- leading to fragile sites, 298–299
- Insertion mutagenesis, from long interspersed repeat retrotransposition, 213
- In situ hybridization, 107–124
 - for banding, 89
 - isochore analysis using, 95–96
 - of labeled DNA, 8
 - for mapping, 438
 - of repetitive and unique DNA sequences, 108–109
- See also* Fluorescence in situ hybridization
- Insulin-like growth factor 2 (IGF2)
 - in Beckwith-Wiedemann syndrome, 313–314
 - roles of the gene product of, 449
- Insulin-like growth factor 2 (IGF2), effect on, of imprinting the *H19* gene, 326–327
- Interchange trisomy, 246
- Interchromosomal effects, 251
- Interferon gene family, functional and nonfunctional genes of, 449
- Interkinesis stage, of meiosis, 134
- Interphase nucleus
 - chromosome domains in, 67–68
 - inactive X chromosomes in, 268
- Interspersed repeats, as hotspots, 215–217
- Intrachromosomal amplification, 374–375
- Intracytoplasmic sperm injection (ICSI), for XXY males, to enable parenthood, 288
- Introns, defined, 8, 442
- Inversion
 - breakpoint hotspots in, 216
 - in hemophilia, 247
 - A, 216–217
 - insertional
 - progeny resulting from, 249–250
 - recombinant chromosomes from, 250
 - pairing configuration in, 129
 - paracentric, 196–197
 - pericentric, 196–197
 - visualization with FISH, 248
 - on the Y chromosome, evolutionary, 456
- Inversion heterozygotes, phenotypes of, 247
- Inversion polymorphisms, 450
- In vitro fertilization, chance of success, 163
- Ionizing radiation, structural aberrations caused by, 210–212
- Isochores, GC- and AT-rich, 95–98, 456–457
- Isochromosomes
 - 3q, in sarcomas, 407
 - defined, 194
- Isodicentric chromosomes, 193–194
- Isodisomy. *See* Uniparental disomy
- Kappa chain gene, in lymphocyte differentiation, 324
- Karyotype, 47–48
 - 45,X, lethality of, 182
 - banded, ideogram of, 89–90
 - C-banded, XY cell, 82
 - chromosome 16, with a fragile site, 296
 - comparing human with cat, 452
 - developed from painting probes, 110
 - diplochromosome, t(5p-;12qt) carrier, 226
 - multiple Y, phenotypes associated with, 288–289
 - pachytene spermatocyte, 144
 - partial, 120
 - of chromosome 5, 120
 - progressive changes in, in cancer, 389
 - Q-banded, XY cell, 81
 - R-banded, XX metaphase spread, 83
 - after in situ hybridization, 112
 - of spontaneously aborted fetuses, 162–163
 - unbalanced duplication/deficiency, phenotypes associated with, 245–246
- See also* Banding; Ideogram
- Kinase, DAP, mediation of apoptosis by, 426
- Kinetochore, 23, 49–54
- Klinefelter syndrome, 259
 - XXY complement associated with, 288
 - discovery of, 4

Index

- Lamins
 - B2, locus of origin of replication of, on chromosome 19, 34
 - domain shared with synaptonemal complex protein1, 143
 - of the nuclear matrix, 68–69
- Langer-Giedion syndrome, deletion in, 230
 - proximity to FRA8R, 297
- Langer mesomelic dwarfism, *SHOX* deletion or mutation in, homozygous, 286
- Lateral asymmetry
 - of C-banding, 85
 - of G and C residues in telomeric repeats, 89
- Lateral elements, of the synaptonemal complex, 143
- Leptotene
 - features of, 127
 - synaptonemal complex assembly in, 143
- Leri-Weill dyschondrosteosis, deletion or mutation of *SHOX* in, heterozygous, 286
- Leukemia cells, HL-60, amplified *MYC* oncogenes in, 373
- Li-Fraumeni syndrome, mutation of *TP53* in, 387
- LINEs. *See* Long interspersed elements
- Linkage disequilibrium, from suppression of genetic recombination, 468
- Linkers, between nucleosome cores, 63
- Lissencephaly, gene responsible for, 231
- Locus control region (LCR), 70
 - for gene clusters, 466
 - for replication, 39
- Long interspersed elements (LINEs), 213
 - evolutionary role of, 449
 - LINE1 repetitive sequences, G-banding from in situ hybridization of, 89
 - characteristics of, 99–100
- Long patch repair, of damaged DNA, 397
- Loops/loop domains
 - chromatin, 63–67
 - correspondence with replicons in size, 34
 - of deoxyribonucleic acid, 71
- Loss of heterozygosity (LOH)
 - cancers caused by, 417
 - in crossing over, mitotic, 356–357
 - from fragile site disruption, 295–297, 424
 - in revertant Bloom cells, 354
- Lung cancer, hotspots of *TP53* in, 396
- Lymphocytes
 - cultured, mitosis in, 21
 - differentiation of, DNA loss in, 324
- Lyon hypothesis, of X chromosome inactivation, 6, 269–271
- Macrochromatin body (MCB), of XX cells, 272
- Major histocompatibility complex (*MHC*) gene locus
 - contents of, 98
 - mapping to chromosome 6, 436
- Males
 - fertility of, 259, 455
 - infertile
 - overrepresentation of balanced reciprocal translocations in population, 240
 - XXY, 288
 - meiosis in, 136–137
 - occurrence of chromosomal abnormalities at, 160
 - recombination frequencies in, 132–133
 - source of gamete causing XO abnormality, 165
 - XX, with translocation of part of Yp, 259–260
 - See also* Y chromosome
- Malignant cells, immortality of, 386
- Mapping
 - chromosome, 431–446
 - genetic, with somatic cell hybrids, 436
 - homozygosity, 434
 - regional, 438
- Mariner* insert-like transposable element, 100
- Markers, polymorphic, for determining the origin of trisomies, 171
- Maternal origin
 - of chromosome 15, in Angelman syndrome, 314–315
 - of chromosome 16, trisomy, 169
 - of chromosome 18, trisomy, 169

- of imprinting, effect in Turner syndrome, 285
- of *KIP2* on chromosome 11, 313–314
- of nondisjunction at meiosis, abnormalities from, 309–310
- of premutation CCG expansion in meiosis, 302–302
- Matrix attachment regions, expressed genes bound to, 70
- Meiosis
 - abnormalities in, 157–174
 - from maternal nondisjunction, 309–310
 - defined, 125
 - details of, 141–155
 - early study of, 2
 - features of, 125–140
 - human chromosome number in, 4
 - translocation originating in, 216
- Meiotic drive, and segregation distortion, 137
- Meiotic recombination
 - frequencies of, assembly into genetic linkage maps, 432–434
 - molecular mechanisms of, 146–149
- Meiotic repair, 208
- Meiotic segregation
 - aberrant
 - in reciprocal translocation carriers, 240–243
 - in Robertsonian translocation carriers, 243–245
 - spontaneous abortion in Robertsonian translocation progeny, 244
- Melanoma, t(12;22) translocation in, and oncogene activation, 411
- Mendelian segregation, basis in meiotic division, 125–126
- Mental retardation
 - in Down syndrome, 176
 - in fragile X syndrome, 300–301
 - overrepresentation of balanced reciprocal translocations in population having, 240
- Mesomelic dwarfism, *SHOX* deletion or mutation in, homozygous, 286
- Messenger ribonucleic acid (mRNA), 3
 - cytoplasmic, size relative to encoding genes, 8
 - transcription of, at the nuclear matrix, 69–70
 - translation into proteins, 55
- Metacentric chromosomes, defined, 46
- Metaphase, 22–23
 - amplified interspersed markers at, 378
 - chromatin packing at, 64
 - chromosome spread after in situ hybridization, 112
 - feature of chromosomes during, 45–47
 - histone-depleted chromosome, 66
 - meiotic, in a spermatocyte, 131
 - nondisjunction arising from premature bivalent separation at, 166
 - polyploid and multipolar, in cervical cancer, 393
 - spermatogonial, 130
 - variations in nuclease sensitivity of chromosomes at, 88–89
- Metaphase chromosome protein 1 (MCP1), 65
- Metaphase plates, 23
 - alloccyclic chromosomes of, 342–343
 - from a neuroblastoma cell line, 371
- Metastasis suppressor genes, 426
- Methotrexate (MTX), 370–374
 - for blocking cell division in the S phase, 84–85
- Methyl-cytosine binding proteins 1 and 2 (MeCP1, MeCP2), 73
- Methyl green, binding to AT base pairs, 85
- Microcell hybrids, 347–348
- Microcephaly, in Wolf-Hirschhorn syndrome, 225–227
- Microdissection, of components of regions at metaphase, for mapping, 438
- Micronuclei
 - formation in amplification, 377
 - induction with spindle poisons, 392
- Microsatellite instability phenotype (MIN phenotype), in colorectal cancer, 392–394
- Microsatellites
 - defined, 302
 - deoxyribonucleic acid of, 101

Index

- Microsatellites (*cont.*):
 as genetic markers for linkage studies, 434
 instability of, mechanisms for reducing, 450
 polymerase chain reaction mapping of, 416
- Microtubule organizing center (MTOC), 22
 centrosome as, 392
- Miller-Dieker syndrome, deletion in, 231
- Minichromosome maintenance proteins (MCM proteins), 39
- Minisatellites, deoxyribonucleic acid of, 101
- Mismatch repair proteins, 33
 genes for, 450
 MLH1, at crossing over sites, 148
- Mitogens, extracellular, triggering of
 immediate early response genes by, 14
- Mitomycin C, whole-arm interchanges
 caused by, 212
- Mitosis, 53
- Mitosis, 13–27
 general features of chromosomes during, 45–59
 nondisjunction in, 310
 switch from, to meiosis, 141–142
 See also Crossing over, in mitosis
- Mitosis-promoting factor (MPF), 18
 in females, 134–136
- Mitotic centromere-associated kinesin (MCAK), 53
- Mixoploidy, 182, 391
- Molecular combing of cosmid DNA fibers, 120
- Molecular hybridization, 8
- Monosomic cell lines, preparing, 349
- Monosomy
 of chromosome 21, 180
 lethality of, 182–183
 tertiary, in translocation, 246
- Mosaicism
 chromosomal
 in Down syndrome, 177
 in Edwards syndrome, 178
 nondisjunction or chromosome loss in, 25, 164
 origin by segregation in a quadriradial, 194–195
 confined placental, 310–311
 defined, 170–171
 diploid/tetraploid, 182
 heterozygosity in females as, 269–271
 for sex chromosomes, 283–294
 trisomy/disomy, 180–181
- Muller's ratchet, on gene degradation in the
 absence of recombination, 455
- Multicolor fluorescence in situ
 hybridization (M-FISH), 117–118
- Multigene family, Keratinocyte growth
 factor, origin of, 449
 olfactory receptor
 characteristics of, 467–468
 facultative heterochromatinization in, 324–325
- Multinucleate cells, 332–333
- Multiple endocrine neoplasia, loss of
 heterozygosity (LOH) in, 424
- Multiple myeloma, t(4;14) in, 410
- Multipolar spindles, in cancer, 391
- Multiradial chromosomes, 333–335
- Muscular dystrophy
 Duchenne
 origins of replication in the gene for, 34
 YAC contig including, 440
 Emery-Dreifuss, emerin defect in, 450
 X-linked
 deletions in, 224
 physical mapping of, 437
- Mutagens/mutagenesis
 chromosome breaks induced by, 208
 insertional, 99
- Mutations
 of the *MECP2* gene in Rett syndrome, 74
 replication error as a cause of, 136–137
 reverse chromosomal, 451
 See also Deletions; Genes, deletion from; Insertion; Repetitive elements
- Mutator phenotypes, 362
 TP53 mutation, 396
- Myotonic dystrophy
 CTG repeat expansion in, 303
 segregation distortion in, 137
- Nail-patella syndrome, 228
- Neocentromeres, 53–54

- Neomycin resistance gene, as a selectable marker, 347–348
- Neoplasia, defined, 385
- Neuronal degeneration, in Down syndrome adults, 176
- Nibrin (p95)
in double-strand breakage, 208
product of *NBS1*, 361
- Nick translation, labeling DNA by, 101–102
- Nijmegen breakage syndrome (NBS), 208, 360–361
- Nomenclature
of banded chromosomes and abnormal karyotypes, 89–92
standard, for chromosome description, 7
- Nondisjunction
from centromere malfunction, 49
defined, 24–25, 157
in females, and absence of a spindle assembly checkpoint, 151
incidence in meiosis and gametes, 159–161
meiotic, causes of, 164
in premature chromatid separation, 24
in spontaneously aborted fetuses, 161–163
- Nuclear envelope, breakdown of, through phosphorylation of nuclear lamins, 18
- Nuclear matrix
defined, 68
metaphase chromosome protein 1 binding to, 65
replication and transcription complexes of, 68–70
replication factories of, 32–33, 37
- Nuclear mitotic apparatus protein (NuMA), complex with dynein, 22
- Nuclease banding, 88–89
- Nucleolar proteins, of the nuclear matrix, 68–69
- Nucleolus, defined, 55
- Nucleolus organizers
appearance of, 46
ribosomal RNA gene clusters as, 24, 55–56
- Nucleosome, packaging of deoxyribonucleic acid in, 62–63
- Nucleotide base pairing, historical demonstration of, 3
- Nucleus, interphase, size of, 68
- Okazaki fragments, 31–33
and dynamic mutation, 302
processing of, by flap endonuclease 1 (FEN-1), 434
- Oncogenes
activation of, 405–414
amplification in cancers, 372–374
cellular, 388
MYC
activation by translocation in Burkitt lymphoma, 407
induction of a catalytic subunit of telomerase by, 41
suppression of, 423–424
translocation activating, 409–411
- One gene-one enzyme hypothesis, 3
- Oogenesis, X chromosome activation during, 328
- Open reading frames, of protein-coding genes, 442
- Origin of replication complex (ORC), 39
- Origins of replication, 33–34
fluorescence in situ hybridization for identifying, 34
- Ovarian cancers, familial, loss of heterozygosity in, 417
- p16, inhibition of CDKs by, 420–421
- p19, inhibition of CDKs by, 420–421
- p21, cell cycle inhibitor, 33
- p53 tumor suppressor protein
activation in DNA damage, 19
in apoptosis, 136
effect on centrosome replication, 392
effector in mitotic and meiotic DNA damage checkpoints, 151
gene for, mutation in carcinogenesis, 19–20, 394
- p57
inhibition of B1 cyclin-dependent kinases by, 422–423

Index

- p57 (*cont.*):
inhibition of cyclin-dependent kinases
by, 313–314
- Pachytene
quadrivalents at, from translocation,
240–241
spermatocyte at
with an XY body, 130
XY pairing segment, 257
synapsis in, 129
- Packaging, of chromosomes, 61–77
- Painting libraries (paints), subchromosomal,
117
- Painting probes, specific, 116
- Paracentric insertion, defined, 201
- Paracentric inversions. *See* Inversion
- Patau syndrome, 178–179
- Paternal origin
of chromosome 15 in Prader-Willi
syndrome, 314
of imprinted genes of placental tissue, 318
of imprinting in Beckwith-Wiedemann
syndrome, 313–314
of intrachromosomal insertion in
chromosome 2, 249
- Pelizaeus-Merzbacher disease, proteolipid
protein gene duplication in,
119–120
- Pericentric inversions. *See* Inversion
- Pericentromeric regions, genomic plasticity
of, 456–457
- Phenotypes
in autosomal aneuploidy or polyploidy,
175–185
in autosomal ring chromosome
formation, 227–228
in fragile X syndrome, 301
in mosaicism of chromosome 21,
180–181
in multiple Y karyotypes, 288–289
- Philadelphia chromosome, association with
chronic myelogenous leukemia, 5,
407–408
- Phosphatases CDC25, activation of mitosis
promoting factor by, 18
- Phosphoglycerate kinase (*PGK*) gene,
expression in the male germline,
328–329
- Phosphorylase kinase subunit B (*PHKB*)
gene, deletion in, 214
- Phosphorylation
activation of proteins in the cell cycle by,
16
of CDC6 and MCM proteins, 39
- Physical maps, genetic, 437–440
- Phytohemagglutinin, effect on division of
blood lymphocytes, 4
- Placental tissue, role of imprinted paternal
genes, 318
- Plasmids, cloning with, 8
- Polar bodies, for preimplantation diagnosis
of aneuploidy, 163
- Poliovirus receptor gene, mapping to
chromosome 19, 436
- Polymerase chain reaction (PCR), 8
for amplifying DNA from single cells,
435
libraries of probes generated by, 116
for localizing an origin of replication,
34
- Polyploidy
arising in endoreduplication, 331–332
defined, 158
origins of, 169–170
- Polysomy X, 287–288
- Positional cloning, for identifying disease
genes, 434
- Prader-Willi syndrome
chromosome 15 alterations in, 314–315
critical region for, 325–327
deletion in, 213, 224
FISH demonstration of, 110, 193
involvement of the *MN7* gene, 215
- Premature chromatid separation (PCS)
malformations resulting from, 24
of mitotic chromosomes, 171
- Premature chromosome condensation
(PCC), 18, 341–343
in Bloom syndrome, 344
- Pre-meiotic synthetic phase, recombination
role of, 148–149
- Pre-mutation, CCG, expansion in maternal
meiosis, 302
- Prenatal diagnosis
of Down syndrome, 176
of Edwards syndrome, 178

- Primary constriction, separation of chromatid arms by, 45–46
- Primed in situ labeling (PRINS), 116
for identifying transposable elements, 100
- Probes, DAZ, for labeling S phase Y chromatin, 113
- Proliferating cell nuclear antigen (PCNA)
of DNA factories, 33
DNA replication checkpoint role of, 19
replication complex of, DNA methylase in, 41
- Prometaphase
formation of the mitotic spindle in, 22
nuclear envelope disappearance in, 133–134
- Promyelocytic leukemia, t(15;17)
translocation in, and oncogene activation, 411
- Prophase
of the cell cycle, 20–21
meiotic pairing in, 148
centrosome separation in, 22
I, of the cell cycle, meiotic, 127
- Protein kinase, phosphorylation of
minichromosome maintenance proteins by, 39
- Proteins
cell cycle regulatory, 15
MDM2, 412
centromeric, functions of, 52–53
chromosomal, 101–103
high mobility group 1 (HMG1), 102
Ikaros family of, transcriptional silencing by, 72
involved in meiotic recombination, 147
mismatch repair, MSH2 and MLH1, 33
See also Cell division cycle proteins; Lamins; numbered series, e.g. p21, p53
- Proteins, specific
BRCA1, role in double-strand break repair, 208
DMC1 and RAD51, role in recombination, 148
EB1 of microtubules, binding by APC, 425–426
GADD45, blocking of DNA replication by, 19
motor
CENP-E, of the kinetochore, 23
dynein, 51–52
Eg5, in centrosome separation, 22
MKLP-1, association with the mitotic spindle, 23–24
MRE11, endonuclease activity of, 208
MSH4, DNA mismatch repair, 148
Polycomb, silencing of homeobox genes, 72
PRC1, effect on cytokinesis, 24
RCC1
DNA-binding protein, 33
identification with CENP-D, 53
SPO11, introduction of double-strand breaks by, 147
- Protooncogenes, 10
role in cancer development, 388, 405–414
TP53, mutation in cancer cells, 373–374
- Pseudoautosomal boundary-like sequences (PABLs), 98
- Pseudoautosomal regions (PARs)
boundary sequence, on Xp and Yp, 98
evolution of, human and mouse models, 454–455
Y chromosome, 257–259
- Pseudogenes, processed, in interspersed repeats, 100
- Pulsed-field gel electrophoresis (PFGE),
identification of amplified genes with, 372
- Pycnodysostosis, isodisomy 1 in, 311
- Q-banding, 80–81
with antibodies to adenosine, 87
with BrdU in the S phase, 85
- Quadriradial configurations
in Bloom syndrome, 354
segregation of, and mosaicism, 194–195
- Quadrivalent with translocation
chromosomes and normal homologues, 240–241

Index

- Quinacrine mustard, fluorescent banding produced by, 7, 80
- Radiation reduction hybrids, chromosome mapping with, 7, 438
- Random-walk/giant loop model, for the interphase chromosome, 68
- R-banding, 83
Alu sequences of, 99
antibodies used in, 87
isochores H1 and H2 associated with, 96–97
sites for synaptic initiation and recombination, 149
within the S phase, 85
- Reannealing, of DNA from separated strands, 107
- Rearrangements, involving multiple chromosomes, 201–202
- Recessive genes, disease, uniparental disomy and expression of, 311. *See also* Genes, specific
- Reciprocal translocations, 197–198
frequency and consequences of, 242–243, 249–251
t(11;22)(*q*23;*q*11), offspring of mothers carrying, 246
t(X;autosome), X inactivation pattern in, 276
- Recombination
double-strand break (DSB) repair model of, 147
ectopic, 449
of Y-linked genes, 455
frequency of, 132–133
and increasing nondisjunction with maternal age, 165
in male meiosis, 259
genetic, 126
meiotic, distribution of sites of, 145–146
within pericentric inversions, 248
- Recombinational DNA repair genes, 397
- Reduction division, meiotic, 125
- Region, chromosomal, defined, 89
- Renaturation, of DNA from separated strands, 107
- Repetitive elements, tandem
mapping with autoradiographic in situ hybridization analysis, 108–109
 α -satellite DNA, 49–51
- Replication
semiconservative, of DNA, 29–31
genes, timing of
in Down syndrome, 177–178
with fluorescence in situ hybridization, 114
- Replication banding, 85
visualization with bromodeoxyuridine (BrdU), 35
- Replication factor C (RF-C), 33
- Replication factories, of the nuclear matrix, 32–33, 37
- Replication fork, 32–33
rate of progression of, 34
- Replicons, defined, 32, 34
- Reporter gene, in transfection, 70
- Reproductive risk, in complex chromosome rearrangement, 247–249
- Restriction endonucleases
for analyzing C-bands, 88
precise cutting of deoxyribonucleic acid by, 432–434
- Restriction fragment length polymorphisms (RFLPs), 434
- Retinoblastoma
D group deletion in, 5
genotype of, 417–418, 437
number of mutations needed to cause, 387
- Retinoblastoma tumor suppressor protein (pRB), role in cell proliferation, 16
- Retinoic acid receptor, binding site for, in an *Alu* subfamily, 99
- Retrotransposons, blocking the mobility of, 451
- Retroviruses, cancer-causing, protooncogenes of, 405
- Rett syndrome, mutations of the *MECP2* gene in, 74
- Reverse banding. *See* R-banding
- Reverse chromosomal mutations, 451
- Reverse chromosome painting, to demonstrate duplications, 193

- Reverse transcriptases
 copy of *Alu* repeats by, 99
 for preparing complementary DNA
 libraries, 442
 telomerase, 40–41
- Rhabdomyosarcoma, t(2;13) translocation
 in, and oncogene activation, 411
- Ribonucleic acid (RNA)
 genes encoding, 442
- Ribonucleoproteins, of the nuclear matrix,
 68–69
- Ribosomal ribonucleic acid (rRNA)
 amplified, in homogeneously stained
 regions, 373
 gene clusters, nucleolus organizer, 24
 genes for, in satellite DNA, 101
 of the nucleolus, 55
 transcription and processing of, in the
 nucleolus, 69
- Ring chromosome
 allocyclic, 342–343
 formation in partial deletions, 191–193,
 227–228
 r21, formation in partial deletions,
 192–193
 rX, phenotype associated with, 273
- Robertsonian translocations (RTs), 199–
 200
 discovery of, 5
 in Down syndrome, 177
 inactivation of excess centromeres in,
 329–330
 male sterility associated with, 239–240
 meiotic segregation in carriers of,
 243–245
- Roberts syndrome, heterochromatin
 abnormalities in, 362
- Rous sarcoma virus, oncogene of, 405–406
- Rubinstein-Taybi syndrome, deletion in,
 228
- Russell-Silver syndrome, uniparental disomy
 in, 312
- Saccaromyces cerevisiae*, homology of genes
 with human genes, 13
- Sarcomas, overexpression of MDM2 cell
 cycle regulator in, 406–407
- Satellite association, defined, 55
- α -Satellite deoxyribonucleic acid
 appearance at synapsis, loops, 143
 at centromeres, 49–51
 fiber length of, 120
 sequences in, 111
 kinetochore assembly at the site of, 53
 for primed in situ labeling, 116
- α -1 Satellites, binding of CENP-C to, 53
- Satellites
 C-banding in, 81
 cytological, 46
 types of DNA of, 101
- Saturation mutagenesis, for identifying
 genes, 448
- Scaffold attachment regions (SARs)
 binding of topoisomerase II to, 20–21
 chromatin loops tethered to, 65–67
- Scaffold-loop model of chromosome
 structure, 63–67
- Scaffold protein
 in chromatin, 61
 chromosomal, 63–67
 SCI (topoisomerase II), 20–21
 in centromeric heterochromatin,
 102–103
 SCII, in centromeric heterochromatin,
 102–103
- Schizophrenia, t(1;11)q(42.2;q21)
 associated with, 438
- Scleroderma, CREST antibodies in, binding
 to the centromere and kinetochore,
 52
- Secondary nondisjunction, in trisomy, 137
 in translocation, 246
- Segmental aneusomy, defined, 223
- Segregation distortion, and meiotic drive,
 137
 in Haw River syndrome, 304
 in spinocerebellar ataxia, 304
- Selectable markers, for constructing
 chromosome-specific microcell
 hybrids, 347–348
- Sex chromatin (Barr body), defined, 6
- Sex chromosomes
 imbalance of, phenotypic effects,
 283–294
 mosaicism of, 170–171
 See also X chromosome; Y chromosome

Index

- Sex determination
 - DMRT1 gene role in, 329
 - genetic basis of, 9–10
 - and the Y chromosome, 255–266
- Sex differentiation, male, SOX9 gene role in, 70
- Sex reversal, male-to-female
 - due to autosomal genes, 261–262
 - in disruption of *DMRT1*, 329
 - XY individuals with excess Xp21, 261
- Sex-specific imprinting, 328–329
- Sex vesicle
 - formation in spermatocytes, 136–137
 - Robertsonian translocations attached to, 239
- Sherman paradox, in fragile X syndrome, 301
- Short interspersed elements (SINEs), 99, 213
- Signaling pathways
 - for blocking replication of damaged DNA, 19
 - cell cycle, activation of, 16–17
 - oncogene products acting in, 406
- SINEs. *See* Short interspersed elements
- Sister chromatid exchange (SCE), 31, 208, 210
 - in Bloom syndrome, 354–355
 - facilitation at fragile sites, 295–297
 - unequal homologous, in
 - intrachromosomal gene amplification, 375
- Sister chromatids
 - formation in the mitotic cell cycle, 13, 45–46
 - separation of
 - kinetochores in anaphase, 23–24
 - in the meiotic division MII, 125
 - role of SCII in, 65
- Smallest region of overlap (SRO), mapping using, 438
- Small nuclear ribonucleic acid genes, transcription of, 69–70
- Small nuclear ribonucleoprotein polypeptide N (SNRPN), 314–315
- Small nuclear ribonucleoproteins (snRNPs), 69
- Smith-Magenis syndrome (SMS), 215–216
 - deletion in, 230
- Somatic cell genetics, 7
- Somatic cell hybrids, 343–345
 - for genetic mapping, 436
- Somatic cells
 - hybridization of, in cytogenetic analysis, 339–351
 - number of chromosomes of, 47
- Southern blotting, defined, 9
- Spectral karyotyping (SKY), 117–118
- Sperm
 - chromosomes of, in meiotic segregation analysis, 249–251
 - estimation of haploid genome size from, 2–3
 - Y-bearing, distinguishing from X-bearing, 256
- Spermatocyte
 - in first meiotic metaphase, 131
 - karyotype at pachytene, 144
- Spindle assembly
 - abnormalities of, and instability of chromosome number, 391–394
 - checkpoint in, 23
 - for DNA damage, 19, 151, 394
 - interference with, by APC protein, 425–426
 - mitotic, 22
- Spindle microtubule attachment, location of, 45–46, 51
- Stability of minichromosome (SMC) family, scaffold protein SCII of, 20, 65
- Stathmin (oncoprotein 18), phosphorylation of, leading to spindle assembly, 18
- Stem cells, telomerase of, 40–41
- Sticky ends
 - defined, 207–208
- Stop codon, defined, 442
- Structural aberrations
 - causes of, 207–221
 - chromosomal, 187–205
- Structural changes, in chromosomes, 394–395
- Submetacentric chromosome, defined, 46
- Superoxide dismutase (*SOD*) gene,
 - overexpression in Down syndrome, 233

- Swyer syndrome, 262
- Synapsis, of homologous chromosomes,
129, 142
- Synaptonemal complex, 142–145
of the XY bivalent, 158
- Synchronization of cell division, 84–85
- Synchrony of replication, and
abnormalities, 464–465
- Synkaryons
defined, 343
- Syntenic genes, defined, 127
- Synteny groups, 435–437
defined, 437
- Synthetic phase (S phase)
of the cell cycle, 7
high-resolution banding in, 84–85
identifying replication sites in, with
[³H]thymidine, 33–34
initiation through cyclin E synthesis, 18
of interphase of the cell cycle, 14
movement of DNA from the replication
factory in, 69
separation of DNA strands in, 29–31
- Tandem repeats, 100–101
mapping with autoradiographic in situ
hybridization analysis, 108–109
of α -satellite DNA, 49–51
- T-banding, 83
of minisatellite deoxyribonucleic acid,
101
- Telocentric chromosome, defined, 46
- Telomerase, and cell aging, 40–41
- Telomere capture, 192
- Telomeres, 54
defective function of, and cell
senescence, 386
evolution of, 456–457
loss of, and dicentric chromosome
formation, 375–376
probes for repetitive sequences of,
fluorescence in situ hybridization,
111
shortening of, questions about, 464
synthesis of, 40
terminal deletions capped by, 192
- Telophase, 24
meiotic, 134
- Teratomas, ovarian, 317–318
- Tertiary trisomy
defined, 137
from translocation, 246
- Testes, XIST RNA in, 273
- Testicular feminization syndrome, 262
- Testis determining factor (*TDF*), 259–260
- Tetraploidy, 182
in gametes, 170
- Thiberge-Weissenbach syndrome, chains
and rings in, 212
- Thymidine, fragile site induction by lack of,
295
- Thymidine kinase (TK), gene for, mapping
to chromosome 17, 436
- Tissue-specific genes
band locations of, 98
in G-bands, 97
- Topoisomerase II (TOPOII)
chromosome condensation changes and,
72
chromosome condensation promotion by,
20–21
of the chromosome scaffold, 65
inhibition of, leading to nondisjunction,
24
mediation of chromosome untangling by,
129
- Transcription
blocking by deacetylation of histones,
72–73
ribonucleic acid, functional
compartmentalization of, 69–70
- Transcription factories, location of, 69
- Transfection
with oncogenes, 406
for studying locus control regions, 70
for studying tumor suppressor genes, 348
- Transformation-associated recombination
cloning, defined, 346
- Translocations
activation of oncogenes by, 409–411
of autosomal genes to the X
chromosome, 453
balanced, phenotypes of, 239–240
breakpoint hotspots in, 216
characteristic synaptic pairing after,
129

Index

- Translocations (*cont.*):
in Edwards syndrome, 178
frequency of male-origin, 161
interchange trisomy due to, 242
physical mapping using, 437
reciprocal, 197–198
 aberrant meiotic segregation in carriers
 of, 240–243
 and oncogene activation, 407–411
 between sex chromosome and
 autosomes, 291
t(11;22), reciprocal, offspring of mothers
 carrying, 246
t(15;17), association with acute
 myelogenous leukemia, 407
t(15;20), centromere inactivation in,
 330–331
t(1;11)
 associated with schizophrenia, 438
 spectral karyotype showing, 119–120
t(2;17), flow karyotype showing, 50
t(4;14), in multiple myeloma, 410
t(6;19), centromere of, 330–331
t(8;14), in Burkitt lymphoma, 407
t(8;17), in lissencephaly, 231
t(9;22)
 in acute lymphatic leukemia (ALL),
 407–408
 in chronic myelogenous leukemia,
 407–408
t(X;14), spreading of inactivation in, 277
t(X;autosome)
 reciprocal, X inactivation pattern in,
 276
 unbalanced, 272
 unbalanced, from carrier mothers, 242
 See also Chromosomes; Robertsonian
 translocation
- Transposable elements
 genome, 9
 mariner insert-like transposable element, 100
 repetitive DNA of, 101
 structural aberrations associated with,
 213–215, 398
- Transposition, initiation by long
 interspersed elements, 99–100
- Transposon-like elements, *mariner*, hotspot
 near, 215
- Trinucleotide expansion
 disorders of, 303
 of repeats, mechanism of, 301–302
- Triploidy, human, association with
 spontaneous abortion, 5, 169,
 181–182
- Triploid zygote, 316–317
- Triradial chromosome, from partial
 endoreduplication, 333
- Trisomy
 21, Y-DNA levels in maternal blood in,
 255–256
 interchange, from translocation, 242
 maternal age effect on incidence of, 165
 mosaicism in, chromosomes exhibiting,
 170
 partial, Down syndrome resulting from,
 232–233
 reproductive consequences in females,
 138
 secondary nondisjunction in, 137
 See also Chromosomes; Down syndrome
- Trophoblast cells, placental, polyploidy in,
 332
- Tubulin
 τ -, of the centrosome, 22
 of kinetochores, 53
- Tumor promoters, gene amplification by,
 411–412
- Tumor suppressor genes, 10
 BRCA1, 417
 inactivation of, and cancer, 415–430
 mutation of, and malignant growth, 388
 RB1, mechanism of action, 418
- Turner syndrome
 association of monosomy XO with, 4
 association of ring-X chromosome with,
 193
 association of X deletions with, 274, 289
 sex chromosome composition in,
 284–285
 spontaneous abortion rate associated
 with, 5
- Two-hit model of carcinogenesis, 417–418
- Ubiquitin-mediated proteolysis
 of cyclin E, 18
 in separation of sister chromatids, 24

- Ubiquitin-protein ligase, targeting of regulatory proteins for proteolysis by, 18
- Uniparental disomy (UPD)
 confined placental mosaicism associated with, 181
 defined, 9, 309–310
- Univalents, at meiosis, 157–159
- Upstream binding factor (UBF), association of ribosomal RNA genes, 54
- Velocardiofacial syndrome, 231–232
- Viruses, cell transformation induced by, 398–399
- von Hippel-Lindau syndrome, loss of heterozygosity in, 417, 425–426
- Web address
 chromosome 6 database and repetitive element database, 100
 comparative genomic hybridization publication list, 121
- Werner syndrome (WS), 361
 helicase mutation in, 354
- Williams-Beuren syndrome, deletions in, 213–214, 224
- Wilms tumors, loss of imprinting in, 398
- Wolf-Hirschhorn critical region gene, 410
- Wolf-Hirschhorn syndrome, 6, 224–227
- X chromosome, 267–281
 active, DNAase 1-sensitive regions of, 102
DIA mapping on, 329
 dystrophin origin of replication on, 34
 evolution of, 452–456
 gene content of, 9–10
 gene for red-green color blindness assigned to, 435
 inactive, 68, 453
 as an example of facultative heterochromatin, 56, 324
 expression of PAR1 genes of, 259
 single active X hypothesis, 269–271
 tissue-specific differences in, 327–328
 isodicentric, 193–194
 long interspersed elements of, 99–100
 misdivision at the centromere, 195
 mutation of the androgen receptor gene of, and sex reversal, 262
 proteolipid protein gene of, at Xq22, 119–120
 skewed inactivation of, 271–272
 termination of replication in, timing of, 35
XIST gene, timing of replication of, 9, 114
- Xeroderma pigmentosum (XP), genes mutated in, 361–362
- XY body, of spermatocytes, 136–137
 at pachytene, 130
- Y chromosome
 evolution of, 452–456
 isodicentric, 194
 and sex determination, 255–266
SRY gene of, in male sexual development, 9
- Yeast artificial chromosomes (YACs)
 cloning DNA fragments in, 440
 cloning human DNA preferentially into, 346
 cloning with, 8, 115–116
 for identifying origins of replication, 34
- Z-DNA, banding produced by antibodies to, 87–88
- Zygotene, 127–129
 synaptonemal complex role during, 142–145